Almonertinib Plus Metronomic Oral Vinorelbine

Sponsor
Fujian Cancer Hospital
Study ID
NCT05663177
Status
Unknown

Conditions

  • EGFR
  • NSCLC
  • Third-generation TKI

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the efficacy of continuing osimertinib in conjunction with metronomic oral vinorelbine after limited progression on osimertinib, to provide clinical experience on the treatment strategy for these patients.

Key Dates

Start date
Dec 20, 2022
Status verified
Dec 2022
Primary completion
Dec 20, 2023
Completion
Jun 1, 2024

Study Design

Enrollment
40 participants (estimated)

Arms

  • Arm: Study arm
    Almonertinib plus metronomic oral vinorelbine

Primary Outcome Measure

PFS [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months ]

Related Studies